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Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance 
treatment: findings of the German randomized controlled trial 
Abstract 
Benzodiazepine (BZD) use has been found to be associated with poorer psychosocial 
adjustment, higher levels of polydrug use and more risk-taking behaviors among opioid 
dependent patients. The aim of this paper is to analyze the correlation between BZD use, BZD 
prescription and treatment outcome among participants in the German trial on heroin assisted 
treatment. 1015 patients who participated in the study comparing heroin assisted and 
methadone maintenance treatment (HAT & MMT) for 12 months were included in the 
analysis. Analyses were carried out to assess the association of treatment outcome with 
baseline BZD use, with ongoing BZD use and with different patterns of BZD prescription. 
Baseline BZD use correlated with lower retention rates but not with poorer outcome. Ongoing 
BZD use correlated with poorer outcomes. Significantly better outcomes were found in the 
course of phobic anxiety symptomatology for those with regular prescription of BZD. The 
percentage of BZD positive urine tests decreased more in HAT than in MMT. Poorer outcome 
for benzodiazepine users may be mediated by a higher severity of addiction. Cautious 
prescribing of benzodiazepines may be beneficial due to the reduction of overall illicit use. 
Keywords: Benzodiazepines, prescriptions, diamorphine, heroin-assisted treatment, 
methadone maintenance, opioid dependence 
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Introduction 
The association between benzodiazepine use and abuse and a more complicated, 
negative clinical course of heroin dependence has been well established. Previous research 
shows that injecting drug users (IDUs) using benzodiazepines (BZDs) are more likely to show 
risk behaviors such as sharing injecting equipment, therefore having a higher rate of hepatitis 
C and polydrug use, and to have more psychosocial problems and higher levels of 
psychopathology (Darke, 1994). When entering methadone maintenance treatment (MMT), 
clients using benzodiazepines are more likely to have a higher severity of addiction, more 
polydrug use and risk behavior, greater number of previous nonfatal overdoses, and more 
mental health and social problems (Bleich et al., 1999; Brands et al., 2008; Darke et al., 1993; 
Meiler et al., 2005).  
Regarding possible interventions for BZD abuse during treatment, Stitzer et al. (1982) 
reported successful use of contingent reinforcement of drug-free urines to minimize the use of 
benzodiazepines among MMT users. An Australian study (Weizman et al., 2003) compared 
two therapeutic modalities for BZD dependent patients in MMT: either BZD detoxification or 
BZD maintenance showing that those maintained on BZD are more successful than those 
detoxified from BZD. In this study, psychiatric comorbidity was positively related to success 
of BZD maintenance treatment. Meiler et al. (2005) analyzed the prescription and use of 
benzodiazepines in a sample of MMT clients and found a high proportion of patients who 
reported medically prescribed BZD use (92.3%). These authors pointed out that physicians 
find themselves in a dilemma: Not prescribing means a high risk of dropout while prescribing 
can risk maintaining BZD dependency. Bramness and Kornør (2007) analyzed BZD 
prescription in methadone and buprenorphine programs in Norway and found a 40% overall 
prescription rate and a mean dose of 36±69 mg Diazepam equivalents. Although it 
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corresponded with the estimated prevalence of anxiety disorders for clients in maintenance 
treatment, the authors outlined the possible negative effects of such a high dose practice.  
An official document of the U.S. Department of Health and Human Services states 
that “the use of benzodiazepines in medication-assisted treatments for opioid addiction, when 
used in prescribed doses, are not dangerous for patients, except when they cause patients to 
seek other drugs with sedative effects” (Batki et al., 2005). Previously, benzodiazepine 
prescription to addicted patients was discouraged despite evidence suggesting it is “helpful to 
a certain population of patients with addictions” (Johnson and Longo, 1998). Seivewright 
and Iqbal (2002) suggest that there is a fine line between misuse and therapeutic use of BZDs 
among drug dependent patients and that prescribing may be helpful but should be done with 
extreme caution. Nevertheless there are no controlled studies offering evidence of benefits or 
disadvantages of BZD prescription in maintenance treatment. 
One study analyzed the impact of benzodiazepine prescription and abuse among 
patients with dual disorders (drug dependence and another mental disorder) in a community 
health system (Brunette et al., 2003). The authors found that the use of prescribed 
benzodiazepines was not related to negative substance abuse outcomes, but these patients 
were more likely to develop benzodiazepine abuse. Furthermore, they reported no 
improvement of depressive or anxious symptoms in patients treated with BZD and 
recommend the use of other treatments. 
The evidence therefore implies that BZD users in MMT can be among the most 
difficult to treat patients. Recently, it has been suggested that more difficult-to-treat patients 
may do better in maintenance treatment using diamorphine (heroin). Clinical studies in 
Switzerland (Perneger et al., 1998; Rehm et al., 2001), the Netherlands (Blanken et al., 2005; 
van den Brink et al., 2003), Spain (March et al., 2006), Germany (Haasen et al., 2007; 
Verthein et al., 2008) and Canada (Oviedo-Joekes et al., 2009) have found heroin-assisted 
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treatment (HAT) to be more effective than MMT in the treatment of methadone non-
responders. However, these studies have not analyzed the effect of HAT compared to MMT 
on BZD use. Furthermore, no studies have been published comparing the outcome of 
maintenance treatment in patients with or without additional prescribed BZD. The objective 
of the present study is to evaluate the prevalence and correlates of BZD use at baseline and 
during treatment as well as patterns of BZD prescription for patients in the German heroin 
trial comparing HAT and MMT in opioid dependent patients.  
Materials and methods 
The German trial on heroin assisted treatment of opioid dependent patients 
HAT and MMT were compared in a multicenter trial among 1015 patients in 7 cities 
in Germany. This sample resulted from screening 2038 heroin dependent patients. Patients 
meeting inclusion and exclusion criteria were randomised into four subgroups depending on 
type of medication (heroin or methadone) and psychosocial care received (psychoeducation 
plus individual counselling or case management plus motivational interviewing). Participants 
were recruited from two target groups: those insufficiently responding to other maintenance 
treatments and those dependent on heroin but not in treatment in the previous 6 months. 
Treatment duration was 12 months. HAT patients received a maximum of three doses of 
intravenous diamorphine (heroin) per day (average dose: 442 mg/d, maximum dose: 1000 
mg/d) with an additional (maximum of) 60 mg oral methadone take-home when needed, 
while MMT patients received one single daily dose of oral methadone individually adjusted 
according to clinical judgement (average dose: 99mg/d). Additional prescription of 
psychopharmacological drugs, including benzodiazepines, was decided for each patient 
individually based upon the respective psychopathology, and there was no restriction on the 
prescription of benzodiazepines. Primary health care was covered by the trial team, referrals 
to other specialists and hospitals occurred for specific treatments. However, as medical 
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coverage in Germany allows patients to consult any doctor, benzodiazepine prescription could 
occur outside the trial coverage, but this was unlikely since there were no restrictions on 
prescriptions of these medications in the frame of the study. Therefore, the use of BZD not 
prescribed in the trial was considered illicit BZD use.  Further details on randomization, 
treatment and outcome were published previously (Haasen et al., 2007). 
Measures. 
For this study, BZD use was assessed according to weekly scheduled urine tests as 
well as self-reports (EuropASI). BZD prescription was extracted from medical prescription 
records. Addiction severity was assessed at baseline, 6 and 12 months using self-reported 
information according to the German version (Gsellhofer et al., 1999) of the EuropASI 
(Kokkevi and Stefanis, 1995) based on the fifth edition of the Addiction Severity Index, ASI 
(McLellan et al., 1992). Psychopathology was assessed with the Global Severity Index (GSI) 
of the Symptom Checklist-90-Revised (SCL-90-R, Derogatis, 1994), with a special focus in 
this study on the anxiety and phobic anxiety subscales assessed at baseline, 1, 3, 6 and 12 
months of treatment. The same two primary outcome measures (POM) as in the overall study 
(Haasen et al., 2007) were used, namely improvement of health and reduction of illicit drug 
use. For the POM on health, study participants were considered responders if they showed at 
least 20% improvement in the Opiate Treatment Index health scale (physical health) and/or at 
least 20% improvement in the GSI (mental health), without a deterioration of more than 20% 
in the other area of health. For the second POM of illicit drug use, participants were 
considered responders if they showed a reduction in the use of street heroin with at least 3 of 
5 negative urines in the month prior to T12 and no increase in cocaine use (hair analysis).  
Double-blind studies have been judged not to be feasible when comparing oral methadone 
with intravenous diamorphine due to methodological and ethical reasons (Bammer et al., 
1999). To avoid treatment bias favoring the experimental treatment, a “worst case analysis” 
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was performed: Drop-outs in the MMT group were considered responders, while those in the 
HAT group were considered non-responders. 
Study population. 
For the purposes of this study, patients were assigned to groups defined by their BZD 
use prior to admission and during treatment and by the pattern of BZD prescribing during 
care: 
1) The full sample was divided into BZD users and non-users at baseline (baseline BZD use 
groups: BZD and NBZD). A patient was considered a BZD user at baseline if he/she reported 
at least one day of BZD use in the last month and/or had a BZD-positive urine at baseline. 
According to these criteria, a total of 736 patients were considered BZD users (72.5%) and 
279 were considered non-users (27.5%). 
2) As longitudinal data on weekly urines were only available over 12 months from patients 
who completed treatment, the analysis of benzodiazepine use during treatment focused on 
treatment completers. From the 1015 subjects in the full sample, 546 completed the treatment 
according to the study protocol [retention rate of 67.2% (n=346) for HAT patients and 40.0% 
(n=200) for MMT patients]. Early termination of study treatment (non-completers) was either 
due to somatic complications, jail terms, violent behaviour, unexcused absence from 
treatment for more than two weeks or excused absence for more than three months. 
Due to the long half-life of benzodiazepines and the resulting long time that they are 
detected in urine samples, a cut-off had to be chosen to differentiate between occasional and 
ongoing BZD use (ongoing BZD use groups). As the mean for BZD positive urines during 
treatment was 26.1% in the group of baseline BZD non-users (see figure 1 below), patients 
were considered ongoing users during treatment (OngBZD group) if they had at least 26.1% 
BZD positive urines during treatment. From the 546 completers, 366 (67%) were considered 
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ongoing users and 180 (33%) had lower rates of positive urines and therefore were considered 
occasional users (OccBZD group). 
3) Completers were split into three groups according to the pattern of benzodiazepine 
prescription (prescription groups). In the OngBZD group, a total of 265 (72.4%, HAT: n=156, 
MMT; n=109) patients did not receive any prescription of benzodiazepines within the study 
treatment during the 12 months of treatment (no prescription group), 46 (12.6%, HAT: n=31, 
MMT; n=15) were prescribed benzodiazepines for no more than 90 days (25.4±24.6, 
range=1-90 days; intermittent prescription group) and 55 (15.0%, HAT: n=31, MMT; n=24) 
for more than 90 days (285.5±90.0, range=108-365 days; regular prescription group). Only 6 
patients from the OccBZD users in the subsample of completers received a BZD prescription 
during treatment (HAT: 2 intermittently, MMT: 3 intermittently and one regularly). 
Data analysis. 
Baseline characteristics were compared between treatment and baseline BZD use 
groups using t-tests for continuous variables and Chi-square tests for nominal variables. Odds 
ratios were calculated to assess differences in treatment outcome and retention between 
baseline and ongoing BZD use. In order to analyze urine samples Friedman tests for non-
parametric repeated measures comparisons were carried out. Pearson correlations were used 
to examine the association between positive urine tests and self-reported information on BZD 
use. 
Regarding ongoing use of BZDs, odds ratios were also calculated to assess differences 
in treatment outcome between ongoing and occasional BZD users in the subsample of 
completers. Two factor RM ANOVAs were used to analyze changes over time in ASI 
Composite Scores (ASI CS) at three time points within treatment groups and ongoing BZD 
use groups. 
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Concerning prescription of BZDs, also in the subsample of completers, binary logistic 
regressions were carried out in order to build an adjusted model to assess the effect of 
treatment, ongoing BZD use and type of prescription on the POMs health and drug use. As 
the type of BZD prescription has three levels, dummy variables were used in the analysis 
(Jaccard, 2001) taking the no prescription group as reference category.  Changes in BZD 
positive urine tests and anxiety symptomatology (SCL-90-R anxiety and phobic anxiety 
subscales over 5 time points) were calculated using two factor RM ANOVAs within treatment 
and prescription groups. 
The alpha level for all analyses was p<.05. All the statistical analyses were conducted 
using SPSS 18.0 for Windows. 
Results 
Baseline BZD use analysis 
Sociodemographic characteristics. 
Table 1 shows sociodemographic data according to baseline BZD use groups and 
treatment groups. BZD users had 12.77±12.26 days of use in the past 30 days prior to baseline 
(HAT group: 12.69±12.22, MMT group: 12.86±12.33, t=-.187, n.s.). The proportion of BZD 
users was not found to be significantly different between treatment groups. Data on drug use, 
physical and mental health and ASI CS are provided in table 1. 
 Table 1.  Baseline characteristics of the full sample (n=1015) according to treatment groups and baseline benzodiazepine use. 
 HAT   MMT    
 BZD NBZD Significance BZD NBZD Significance Total significance between BZD and 
NBZD 
Sociodemographic characteristics        
Female gender (n,%)1 
73, 19.6 30, 21.0 2=.119, p=.731 66, 18.1 35, 25.7 2= 3.551, 
p=.060 
2= 2.452, p=.117 
Age (mean±SD)1 
36.06±6.57 36.52±6.94 t=-.702, p=.483 36.27±6.59 37.33±7.28 t=-2.293, p=.022 t=-1.591, p=.112 
Education in years (mean±SD)2 
9.75±1.83 10.01±1.65 t=-1.453, p=.147 9.71±1.86 9.89±1.88 t=-.985, p=.325 t=-1.724, p=.085 
Employed (n,%)4 
44, 11.9 23, 13.29 2=1.781, p=.182 41, 11.3 23, 16.9 2= 2.792, 
p<.095 
2= 4.504, p=.034 
Stable housing (n,%)3 
247, 66.6 107, 75.4 2= 3.697, 
p=.054 
253, 69.5 96, 70.6 2=.055, p=.814 2= 2.369, p=.124 
Information on heroin use (mean±SD) 
       
Age of beginning of use2 
19.78±5.34 20.59±5.38 t=-1.524, p=.128 20.00±5.18 21.20±5.31 t=-2.293, p=.022 t=-2.681, p=.002 
Years of use2 
13.65±6.18 13.61±6.72 t=.072, p=.943 13.90±6.39 12.83±6.14 t=1.677, p=.094 t=1.220, p=.223 
Days of use in the past 30 days4 
20.79±10.89 22.85±10.42 t=-1.949, p=.052  20.59±10.82 22.34±10.94 t=-1.599, p=.110 t=-2.516, p=.012 
Physical health 
       
OTI health scale (0-50 pts, mean±SD) 1 
18.70±5.23 18.89±5.16 t=-.364, p=.716 19.38±5.43 18.49±5.22 t=1.661, p=.097 t=.930, p=.352 
HIV positive (n,%)5 
35, 9.4 9, 6.5 2= 1.123, 
p=.289 
39, 10.8 8, 5.9 2= 2.725, 
p=.099 
2= 3.695, p=.055 
HCV positive (n,%) 5 
300, 81.1 110, 79.1 2=.244, p=.621 302, 83.4 105, 77.8 2= 2.115, 
p=.146 
2= 1.860, p=.173 
Mental health 
       
At least one comorbid diagnostic; F2-F5 (n, %)12 
190, 63.1 63, 52.5 2= 4.037, 93, 64.6 33, 54.1 2= 1.989, 2= 6.003, p=.014 
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p=.045 p=.158 
SCL-90-R GSI (T value) (mean ± SD) 1 
69.86±10.42 66.41±11.86 t=3.051, p=.003 70.42±9.64 67.78±10.13 t=2.691, p=.007 t=4.034, p<.0001 
SCL-90-R Anxiety value (mean ± SD) 1 
1.08±0.74 .93±.76 t=2.061, p=.040 1.13±.79 .95±.77 t=2.178, p=.030 t=3.005, p=.003 
SCL-90-R Phobic anxiety value (mean ± SD) 1 
.68±.68 .62±.68 t=.954, p=.340 .73±.70 .58±.65 t=2.166, p=.031 t=2.207, p=.028 
Addiction Severity Index Composite Scores at baseline 
(mean±SD) 
       
Physical state of health5 
.44±.34 0.37±0.31 t=1.999, p=.046 0.43±0.35 0.38±0.35 t=1.690, p=.092 t=2.606, p=.009 
Economic situation6 
.92±.22 .90±.27 t=1.058, p=.291 .95±.17 .87±.29 t=3.855, p=.003 t=3.325, p<.001 
Satisfaction from work13 
.39±.33 .39±.36 t=-.030, p=.976 .35±.34 .35±.33 t=.037, p=.970 t=.010, p=.992 
Drug use8 
.39±.10 .35±.09 t=4.666, p<.0001 .40±.10 .35±.09 t=4.863, p<.0001 t=7.113, p<.0001 
Alcohol use9 
.12±.18 .12±.20 t=-.128, p=.898 .13±.20 .09±.17 t=2.028, p=.044 t=1.258, p=.209 
Legal status and problems11 
.43±.27 .37±.27 t=2.160, p=.031 .42±.27 .34±.26 t=2.917, p=.004 t=3.573. p<.0001 
Family relationships7 
.29±.21 .24±.20 t=2.385, p=.017 .28±.20 .24±.20 t=1.720, p=.086 t=2.918. p=.004 
Social environment relationships10 
.24±.20 .24±.21 t=1.441, p=.150 .29±.22 .26±.22 t=1.432, p=.153 t=2.027. p=.043 
Mental status8 
0.26±0.21 0.18±0.19 t=3.868, p<.0001 0.26±0.23 0.20±0.20 t=2.842, p<.005 t=4.735. p<.0001 
 
Sample size: 1 n=1015, 2 n=1014, 3 n=1013, 4 n=1011, 5 n=1006, 6 n=988, 7 n= 985, 8 n=968, 9 n= 965, 10 n=953, 11 n=951, 12 n=626, 13 n=436 
HAT: Heroin Assisted Treatment group (total n=515); MMT: Methadone Maintenance Treatment group (total n=500). 
BZD: BZD use at baseline; NBZD: No BZD use at baseline (criteria: positive urine or at least one day of use in the last 30 days at baseline examination). 
 BZD users at baseline were found to be less often employed, initiated heroin use at an 
earlier age, had less days of heroin use in the past month but more days of cannabis use, were 
more likely to have a comorbid diagnosis, and have higher SCL-90-R T anxiety and phobic 
anxiety subscale scores. Regarding ASI CS, they had higher scores (indicating higher 
severity) for physical state of health, economic situation, drug use, legal problems, family, 
social relations and mental status areas. Although not statistically significant, BZD users were 
more likely to be HIV positive. 
Relation of baseline BZD use with treatment retention and outcome. 
Table 2 shows treatment retention and POMs by treatment group and BZD use at 
baseline. A statistically significant higher retention rate can be observed in those patients who 
did not use benzodiazepines at baseline. This difference is significant only in the HAT 
treatment group, not in the MMT group. No significant differences were detected in outcome 
measures. 
 Table 2: Treatment retention and primary outcome measure (POM) response according to treatment groups and baseline benzodiazepine use (n, 
%) in the full sample*. 
 HAT   MMT   Total   
 BZD NBZD Significance BZD NBZD Significance BZD NBZD Total significance 
between BZD and 
NBZD 
12 months 
retention 
240, 
64.5 
106, 
74.1 
OR= .635, 95% 
CI=. .413-976; 
p=.038 
140, 
38.5 
60, 
44.1 
OR=.792 , 95% CI= 
.531-1.180; p=.251 
380, 
51.63 
166, 
59.50 
OR=.727, 95% CI= 
.550-.961; p=.025 
POM reduction of 
illicit drug use  
250, 
67,2 
106, 
74.1 
OR= .715, 95% 
CI= .464-1.102; 
p=.128 
209, 
57.4 
67, 
49.3 
OR= 1.389, 95% 
CI= .935-2.062; 
p=.103 
459, 
62.36 
173, 
62.01 
OR=1.015 , 95% 
CI= .764-1.349; 
p=.917 
POM health 
improvement 
293, 
78.8 
119, 
83.2 
OR= .748, 95% 
CI= .452-1.238; 
p=.258 
269, 
73.9 
101, 
74.3 
OR= .981, 95% CI= 
.626-1.539; p=.934 
562, 
76.36 
220, 
78.85 
OR=.866 , 95% CI= 
.620-1.210; p=.399 
 
*These variables were measured for all the participants and therefore there are no missing values (n=1015, HAT n=515, MMT n=500). 
BZD: BZD use at baseline (report of at least one day of BZD use in the last month and/or positive urine analysis at baseline), NBZD: No BZD 
use at baseline, POM: Primary Outcome Measure 
 BZD use during treatment. 
Figure 1 shows weekly percentage of all treated patients with BZD positive tests in 
urine samples during the 12-month treatment period according to treatment and baseline BZD 
use groups, with a greater decrease in BZD positive tests in the HAT treatment group. The 
mean for BZD positive tests in urine samples was 52.3% for HAT patients and 60.3% for 
MMT patients. A Friedman test carried out with the full sample showed a significantly greater 
reduction in BZD positive urines for HAT patients compared to MMT patients (Friedman’s 
2=50.074, p<.0001). Baseline BZD users had an average of 67.2% positive tests and 
baseline non-users of 26.1% in the 12-month treatment period. Among baseline BZD users, 
HAT patients showed a greater but not significant reduction in BZD positive tests in urine 
samples (mean of positives; HAT: 64.3%, MMT: 65.9%), while among baseline non-users the 
percentage BZD positive urines was less in HAT than MMT patients (mean of positives; 
HAT: 21.8%, MMT: 28.1%). The proportion of BZD positive tests in urine samples showed 
positive correlations with ASI information on BZD use in the last 30 days at both baseline 
(full sample r=.464, p<.0001, completers r=.499, p<.0001) and at 12 months (full sample 
r=.499, p<.0001, completers r=.492, p<.0001). 
Ongoing BZD use analysis 
Using the cut-off of 26.1% of BZD positive urines to differentiate between occasional 
and ongoing users, correspondence of BZD baseline and ongoing use was significantly high 
(2= 107.033, p<.0001), showing that 80.8% of the baseline users remained ongoing users 
while only 35.5% of the baseline non users became ongoing users. 
 Figure 1. Percentage of positive benzodiazepine urines by treatment group (left) and by baseline BZD use (right) for the full sample*. 
 
 
 
 
 
 
 
 
 
 
 
* Urine tests were scheduled weekly for all the patients in treatment (n=1015). At baseline 984 urines were tested. During treatment, missing 
urine samples ranged from 209 to 519. 
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Table 3: Primary outcome measure (POM) response according to treatment groups and ongoing benzodiazepine use (n, %) in the sample of 
completers*. 
 
 HAT   MMT   Total   
 OngBZD OccBZD Significance OngBZD OccBZD Significance OngBZD OccBZD Total significance 
between OngBZD and 
OccBZD 
POM reduction of 
illicit drug use  
153, 70.2 100,  
78.1 
OR=.659, 95% CI= 
.396 -1.097 ; p=.108 
74,  
50.1 
29, 55.8 OR=.793, 95% CI= 
.420 -1.497 ; p=.474 
227, 62.0 129, 
71.7 
OR=.646, 95% CI= .439 
-.516 ; p=.026 
POM health 
improvement 
183, 83.9 118, 
92.2 
OR=.443, 95% CI= 
.211 -.929 ; p=.028 
106, 71.6 48, 92.3 OR=.210, 95% CI= 
.071 -.620 ; p=.002 
289, 79.0 166, 
92.2 
OR=.317, 95% CI= .174 
-.577 ; p<.0001 
 *This table was calculated using data from the participants who completed the treatment (n=546, HAT n=346, MMT n=200). 
OngBZD: ongoing BZD use; OccBZD: Occasional BZD use (less than 26.1% positive urines during treatment). 
 Ongoing BZD use relation with treatment outcomes. 
Table 3 shows POMs by treatment and ongoing benzodiazepine use in the subsample 
of completers (n=546). Ongoing BZD use was found to have a negative association with 
health outcome in both treatment groups but, when analyzing drug use outcome, differences 
were only statistically significant when both treatment groups were combined. 
Results of the repeated measures analysis of variance of ASI composite scores (CS) 
showed that ongoing BZD use was statistically associated with significantly poorer results in 
CS for satisfaction from work (Pillai’s Trace=.072, F=3.320, p<.05), alcohol use (Pillai’s 
Trace=.025, F=6.004, p<.005) and  social relationships (Pillai’s Trace=.013, F=2.975, p<.05), 
while HAT patients with ongoing BZD use performed better on CS for alcohol use (Pillai’s 
Trace=.044, F=11.008, p<.0001), drug use (Pillai’s Trace=.186, F=51.524, p<.0001), and 
legal status and problems (Pillai’s Trace=.026, F=6.275, p=.002) compared to MMT patients 
with ongoing BZD use. 
BZD prescription analysis 
Type of benzodiazepine prescribed. 
Among completers, patients were prescribed diazepam (n=75, 69.5%), clonazepam 
(n=15, 13.9%), flunitrazepam (n=7, 6.5%), oxazepam (n=3, 2.8%), lorazepam (n=3, 2.8%), 
clorazepate (n=2, 1.9%), temazepam, nitrazepam and lormetazepam (n=1 each, 0.9%). During 
treatment, 21 (19.4%) of these patients had a prescription change to another type of 
benzodiazepine. 
BZD prescription and outcome measures. 
The results of the adjusted model for the sample of treatment completers receiving 
prescribed benzodiazepines, with ongoing BZD use and treatment groups as independent 
variables, showed that only treatment group was a reliable predictor of the POM on drug use 
with better results for the HAT group (OR=2.513, 95%CI=1.738-3.634). Belonging to the 
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HAT treatment group and having an occasional BZD use predicted better results for the POM 
on health (Treatment: OR=1.802, 95%CI=1.113-2.866; Ongoing BZD use: OR=.331, 
95%CI=.178-.615).  Regarding prescription patterns, no significant differences were found 
when comparing regular or irregular prescription with no prescription at all. For the POM on 
health, the intermittent prescription group (OR=.438, 95%CI=.166-1.157) as well as the 
regular prescription group (OR=1.326, 95%CI=.683-2.575) did not differ significantly from 
the no prescription group. For the POM on drug use, the intermittent prescription group 
(OR=1.357, 95%CI=.745-2.538) as well as the regular prescription group (OR=.812, 
95%CI=.438-1.507) did not differ significantly from the no prescription group. 
Course of anxiety symptomatology according to pattern of BZD prescription. 
SCL-90-R scores for anxiety and phobic anxiety by treatment group in the completers 
sample can be seen in figure 2. Both scores showed a significant time effect (anxiety: Pillais 
trace=.170, F=25.949, p>.0001; phobic anxiety: Pillais Trace=.129, F=18.791, p>.0001). 
Despite a greater decrease in anxiety and phobic anxiety scores in the HAT group, the effects 
were not statistically significant for treatment groups (anxiety: Pillais Trace=.010, F=1.317, 
p=.262; phobic anxiety: Pillais Trace=.033, F=.164, p=.686). Nevertheless a significant effect 
of BZD prescription was detected in phobic anxiety (Pillais Trace=.045, F=2.928, p<.005), 
reflecting a higher decrease of phobic anxiety in the regular prescription group.
 Figure 2. Anxiety (left) and phobic anxiety (right) GSL SCL-90-R scores by treatment group in the subsample of completers*. 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Scores calculated in the subsample of completers (n=546) in those patients whose anxiety levels were registered in all the 5 time points 
(N=516, HAT n=330, MMT n=186). 
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Discussion 
Benzodiazepine use at treatment entry and during opioid maintenance treatment is a 
marker for greater complexity of patient need and poorer treatment outcomes in previous 
studies. This study confirms several findings of previous studies including: BZD use at 
treatment entry is associated with more severe problems related to drug use, physical health 
and psychosocial function, and an earlier age of initiation of heroin use; BZD use at baseline 
is highly correlated with ongoing BZD use during treatment; ongoing BZD use during 
methadone maintenance treatment is associated with poorer treatment outcome but does not 
lead to decreased treatment retention in MMT (Brands et al., 2008). 
This study extends the findings from previous studies by also evaluating the impact of 
BZD use on outcomes from Heroin-Assisted Treatment (HAT). Using an intent-to-treat 
analysis and predefined primary outcome measures, the present study showed no negative 
impact of BZD use on treatment outcomes from HAT. This may be related to the generally 
negative outcomes for those who leave treatment regardless of BZD use. Baseline BZD use 
also led to poorer treatment retention in HAT, distinct from the absence of such an effect on 
MMT retention. BZD use has been linked to increased rates of non-fatal overdose in heroin 
users (Kerr et al., 2005) and it is possible that the negative impact on HAT retention arises 
from increased sedation among BZD users limiting the ability to prescribe an effective dose 
of diamorphine. 
Focussing only on treatment completers, ongoing BZD use during care is associated 
with poorer outcomes in both MMT and HAT for health and poorer outcomes for drug use 
when both opioid treatment groups are combined. BZD users however had a greater reduction 
in BZD use and better outcomes for drug use, alcohol use and legal problems when treated 
with HAT than with MMT. This suggests that HAT may be a preferred treatment option for 
long-term opioid dependent patients with benzodiazepine dependence despite the reduced 
treatment retention discussed above. 
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In this study, benzodiazepine users at baseline had a higher level of mental distress 
and greater levels of anxiety and phobic anxiety. This suggests that the illicit use of 
benzodiazepines in this patient population may arise from underlying mental health issues.  
Indeed, those patients with ongoing BZD use who were prescribed benzodiazepines during 
the study reported a greater reduction in phobic anxiety symptoms. In general, prescription of 
benzodiazepines during maintenance treatment has been cautiously suggested for some 
patients. Only one in four patients with ongoing BZD use received a benzodiazepine 
prescription during the trial, about half of them received a prescription not just intermittently, 
but on a regular basis, demonstrating how cautiously benzodiazepines were prescribed despite 
the high level of mental health problems. This suggests that illicit benzodiazepine use remains 
an important factor to consider. However, the results do not show significant outcome 
differences between the two prescription groups and the group with ongoing illicit BZD use. 
Considering the fact that illicit BZD use is also associated with illicit polydrug use as well as 
criminal behavior, loosening the restrictive criteria for prescribing BZD (if indicated) in this 
population may be recommended in order to a) avoid illicit BZD use, b) have some input in 
the type of medication (short or long term, side effects) and c) have better dosage control. 
Future randomized studies evaluating the impact of prescribing benzodiazepines to opioid 
maintenance treatment patients with ongoing BZD use may be warranted to clarify the 
clinical situations in which this is in the best interests of patients. 
With respect to the choice of opioid maintenance treatment in the face of BZD use, 
HAT seems to be associated with a lower percentage of positive BZD urine tests during the 
12 months, and ongoing BZD users in HAT showed better outcome measures than those in 
MMT in some of the composite scores for addiction severity. Illicit benzodiazepine use 
should be seen in a broader context of polydrug use, where additional sedation of 
benzodiazepines may be wanted to balance out other effects of illicit drugs such as cocaine 
and street heroin. Therefore, the overall better effect of HAT in reducing illicit drug use 
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(Haasen et al., 2007; March et al., 2006; van den Brink et al., 2003) may be associated with 
the reduction of benzodiazepine use. The stronger association of HAT and BZD decrease may 
also be explained in part by neurobiological aspects, which could also explain why BZD use 
is lower among heroin dependents not in maintenance treatment (Backmund et al., 2005). 
Benzodiazepines, especially flunitrazepam, have been found to boost the subjective effects of 
methadone (Busto et al., 1996), and diazepam has been found to increase the effect of 
methadone by some undetermined mechanism (Eap et al., 2002). BZD effects have yet to be 
shown in an interaction with diamorphine (heroin) and may well differ considering the 
different pharmacokinetic profiles of diamorphine and methadone. The greater dopamine 
release of diamorphine in the mesolimbic dopamine system (Devine et al., 1993) may also 
lead to less concomitant BZD use. It has been shown that chronic treatment with opiates alters 
BZD receptor binding and GABAA receptor function (Lopez et al., 1990; Sivam and Ho, 
1982), and it is possible that various opiate ligands exert differential effects on the GABAA 
receptor. These neurobiological aspects will have to be examined in future experimental 
studies. 
There are limitations of this study that need to be considered. The study was not set 
out to analyze the effect of maintenance treatment on benzodiazepine use, so no causality can 
be attributed and the associations found need to be confirmed in future trials. The patient 
groups are not randomized according to BZD use, and baseline differences – such as more 
mental distress among BZD users – are not controlled for. Furthermore, there is no data on 
prescription of BZD by other doctors, as well as no possibility to distinguish between 
prescribed and non-prescribed BZD at baseline. Finally, the differentiation between 
occasional and ongoing BZD use needs to be validated in future studies, as the cut-off used in 
this study may not be sufficiently reliable. 
The results confirm the cautious attitude towards prescribing benzodiazepines of 
physicians in maintenance treatment, but also suggest that benzodiazepine prescription may 
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not have to be considered so restrictively in difficult-to-treat opioid dependent patients. These 
findings may need to be reflected in treatment guidelines. Future research will have to 
determine whether the correlation with negative treatment outcome is due to BZD use, or 
whether improvement during treatment leads to lower BZD demand.  
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